Huminsulin Normal

Huminsulin Normal is a recombinant human insulin (Insulin human, rDNA) marketed in the European Union. It is supplied as an injectable solution, though the exact strength and dosage form are not specified in the available data. As a prescription‑only medication, Huminsulin Normal belongs to the insulin class of antidiabetic agents and is used to replace or supplement endogenous insulin in patients with diabetes mellitus type 1 or type 2.

Huminsulin Normal is prescribed to improve blood‑glucose control in patients diagnosed with diabetes mellitus.

- For adults and children with type 1 diabetes requiring basal and prandial insulin coverage. - As part of a comprehensive regimen for type 2 diabetes when oral agents are insufficient. - To provide insulin supplementation during periods of increased metabolic demand, such as surgery or illness. - In combination with diet and exercise to achieve target glycemic goals. - As an option for managing hyperglycemia in pregnant women with pre‑existing diabetes, when clinically indicated.

Adverse reactions may occur with any insulin product. The frequency and severity vary among individuals.

Common: - Mild hypoglycemia (low blood sugar) - Injection site redness, swelling or itching - Lipodystrophy (localized fat loss or accumulation) - Weight gain - Transient headache

Serious: - Severe hypoglycemia with neuroglycopenic symptoms - Allergic reactions such as urticaria, angioedema or anaphylaxis - Insulin edema leading to peripheral swelling - Hypokalemia associated with rapid glucose shifts - Rare cases of insulin‑induced hypoglycemic coma

Huminsulin Normal should be used with careful monitoring and awareness of specific safety considerations.

- Adjust dose based on frequent blood glucose measurements to avoid hypoglycemia. - Use caution in patients with renal or hepatic impairment, as insulin clearance may be reduced. - Consider lower initial doses in elderly patients or those with limited caloric intake. - Evaluate for possible allergic reactions, especially with a history of insulin sensitivity. - Do not use in patients experiencing acute illness or infection without dose reassessment. - Counsel patients on proper injection technique to minimize lipodystrophy. - Pregnant or breastfeeding women should follow obstetric guidance before initiating therapy.

Certain medicines and clinical conditions can alter the glucose‑lowering effect of Huminsulin Normal.

Avoid: - Concurrent use of other rapid‑acting insulins or insulin analogues without dose adjustment. - Beta‑blockers that may mask hypoglycemia symptoms. - High‑dose corticosteroids that increase insulin resistance. - MAO‑inhibitors combined with sympathomimetic agents, which can affect glucose metabolism.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Thiazide diuretics that may raise blood glucose levels. - ACE inhibitors or ARBs, which can potentiate insulin’s effect. - Alcohol consumption, as it can cause delayed hypoglycemia. - Thyroid hormones, which may modify insulin requirements.